SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2023 financial and operating results after the market closes on Monday, August 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
To participate in the conference call by telephone, dial (800) 715-9871 or (646) 307-1963 and reference Maravai LifeSciences, Conference ID 8704315. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
| Last Trade: | US$1.72 |
| Daily Change: | -0.01 -0.58 |
| Daily Volume: | 1,180,316 |
| Market Cap: | US$243.960M |
February 04, 2025 January 28, 2025 January 08, 2025 December 05, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
